Advanced Biomed Inc. (ADVB)
Nasdaq · Healthcare · Diagnostics & Research
$6.34−9.94%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $10.5M
- P/E (trailing)
- 1.3
- 52-week range
- $3.61 – $24.23
- 52-week change
- −29.31%
- EPS (trailing)
- $4.85
Fiscal year to Jun 2025
- Net income
- −$3.3M
- Diluted EPS
- −$0.16
- Free cash flow
- −$5.9M
From the company’s annual report on SEC EDGAR.
About Advanced Biomed Inc.
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also offers microfluidic biochips, such as A+Pre, AC-1000 CTC enrichment, and A+CellScan chips to provide assay products and services to cancer patients.
Headquarters: New York, United States · 31 employees · advanbiomed.com